This trial is testing a combination of immunotherapy and targeted therapy as a treatment for colorectal cancer that has spread to the liver and can be removed by surgery.
2 Primary · 13 Secondary · Reporting Duration: Up to 2 years
Experimental Treatment
19 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: